Abstract: Arylthioalkylphenylcarboxylic acids are provided which have the structure ##STR1## wherein Ar represents an aryl group including phenyl or naphthyl which may or may not include one or more substituents, X is COOR where R is hydrogen, alkali metal, or lower alkyl, or X is 5-tetrazolyl or ##STR2## where R.sup.1 is lower alkyl or aryl, p is 1 to 5, and m is 1 to 4. These compounds are cardiovascular agents which exhibit thromboxane antagonist activity and thus are useful in the treatment of thrombotic and vasopastic diseases.

Abstract: 7-Oxabicycloheptane imidazole prostaglandin analogs are provided which are useful in treating thrombotic and vasospastic disease and have the structural formula ##STR1## wherein m is 0, 1, 2, 3 or 4; n is 1, 2 or 3; and p is 1, 2 or 3; Z is --CH.dbd.CH--, --CH.sub.2 CH.sub.2 -- or ##STR2## wherein Y is 1 or a single bond; R is CO.sub.2 H, CO.sub.2 lower alkyl, CO.sub.2 alkali metal, CONHSO.sub.2 R.sub.2 (wherein R.sub.2 is lower alkyl or aryl) or --CH.sub.2 -5-tetrazolyl; A is CHOH, C.dbd.O, ##STR3## (wherein R.sub.3 is H or lower alkyl), or a single bond; R.sub.1 is lower alkyl, aryl, cycloalkyl or H, R.sub.1 can be H only when A is a single bond.

Abstract: Novel thromboxane receptor antagonists are disclosed, having the formula ##STR1## wherein: A is aryl, optionally substituted withhalogen,lower alkoxy,carboalkoxy,lower alkyl,alkylamino, orphenyl;X is --CH.sub.2 or --NH;R.sub.1 is COOH, COO-alkali metal (such as Na, K, or Li), COO-lower alkyl, CONHSO.sub.2 R.sub.2, or 5-tetrazolyl;R.sub.2 is lower alkyl or aryl;m is 0, 1, or 2; andp is 2, 3, 4 or 5.Also disclosed are novel intermediates of formula I compounds.

Abstract: Novel cyclopropyl aza prostaglandin analogs are disclosed having the formula ##STR1## wherein A can be carbonyl, sulfonyl or a single bond. These compounds are useful, for example, as thromboxane antagonists.

Abstract: Phenylsulfone alkenoic acids and derivatives thereof are provided which have the structure ##STR1## wherein Ar represents an aryl group including phenyl or naphthyl which may or may not include one or more substituents, X is COOR wherein R is hydrogen, alkali metal or lower alkyl or X is 5-tetrazolyl or ##STR2## wherein R' is lower alkyl or aryl; n is 2, 3 or 4 and m is 2, 3 or 4. These compounds are cardiovascular agents which exhibit thromboxane antagonist activity and thus are useful in the treatment of thrombotic and vasospastic disease.

Abstract: 7-Oxabicycloheptane imino interphenylene substituted prostaglandin analogs are provided having the structural formula ##STR1## wherein n is 1 or 2; m is 1 or 2; R is H, lower alkyl, or alkali metal; and R.sup.1 is --OR.sup.2, ##STR2## where R.sup.2 is lower alkyl, aryl, aralkyl, cycloalkylalkyl, alkanoyl or aroyl; and R.sup.3 is lower alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy, --NHaralkyl, --NHalkyl, --NHalkylcycloalkyl or --NHaryl.These compounds are cardiovascular agents which exhibit thromboxane antagonist activity and thus are useful in the treatment of thrombotic and vasospastic disease.

Abstract: Geminally-substituted cyclic ether carboxylic acids or derivatives thereof are provided which have the structure ##STR1## wherein Z is aryl, which may be optionally substituted with one or more of the following groups: halo, lower alkyl, lower alkoxy, hydroxy, lower alkylamino, phenyl or carbo-lower alkoxy ##STR2## R is COOH, COO alkali metal, coo lower alkyl, ##STR3## R.sup.1 is lower alkyl or aryl; n is 1 or 2;p is 2 to 5; andq is 1 to 4.These compounds are cardiovascular agents which exhibit thromboxane antagonist activity and thus are useful in the treatment of thrombotic disease.

Abstract: Arylthioalkylphenylcarboxylic acids are provided which have the structure ##STR1## wherein Ar represents an aryl group including phenyl or naphthyl which may or may not include one or more substituents, A is ##STR2## R is hydrogen, alkali metal or lower alkyl, m is 0, 1, 2, or 3, n is 0, 1, or 2, p is 1 to 5, q, is 0, 1, 2, or 3, r is 0, 1, 2, or 3. These compounds are cardiovascular agents which exhibit thromboxane antagonist activity and thus are useful in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane substituted amino prostaglandin analogs are provided having the structural formula ##STR1## wherein n is 1 to 5; R.sup.1 is CO.sub.2 H, CO.sub.2 lower alkyl or ##STR2## and R.sup.2 is ##STR3## wherein R.sup.3 is lower alkyl, aralkyl, --NHalkyl or --NHaryl, or R.sup.2 is ##STR4## wherein q is 1 to 12, and R.sup.4 is lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S--, aryl-S--, arylalkyl-S--, ##STR5## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease and are useful in the preparation of radiolabelled analogs.

Abstract: Bicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; Q is --CH.dbd.CH--, --CH.sub.2 --, ##STR2## or a single bond; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR3## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S-, aryl-S-, arylalkyl-S-, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.

Abstract: 7-Oxabicycloheptane substituted oxo prostaglandin analogs are provided having the structural formula ##STR1## wherein R.sup.1 is lower alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl, A is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --, n is 1 to 4, m is 1 to 8, and R.sup.2 is ##STR2## wherein R.sup.4 is H or lower alkyl and including all steroisomers thereof.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane substituted diacid diamide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH ##STR2## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 and R.sup.3 are the same or different and are H, lower alkly, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aralkyloxy, cycloalkyl or cycloalkylalkyl.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: Cis-exo 7-oxabicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR2## wherein R.sup.2 and R.sup.3 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.2 and R.sup.3 being other than hydroxy and lower alkoxy; X is O, NH, CH.dbd.CH, or --(CH.sub.2).sub.x wherein x is 0 or 1; and R.sup.1 is lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, amino, alkylamino, arylamino, arylthio or alkylthio.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: Bicycloheptane substituted ether prostaglandin analogs are provided having the structural formula ##STR1## wherein X is O or ##STR2## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane substituted prostaglandin alcohols are provided having the structural formula ##STR1## wherein A is --CH.dbd.CH-- or (CH.sub.2).sub.2 ; m is 1 to 5; Q is --CH.dbd.CH-- or (CH.sub.2).sub.2 ; R is H, alkali metal or alkyl; and R.sup.2 is ##STR2## wherein R.sup.3 is H or lower alkyl and R.sup.4 is H or I and including all steroisomers thereof.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane substituted ether prostaglandin analogs are provided having the structural formula ##STR1## wherein X is O or ##STR2## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane substituted thio prostaglandin analogs are provided having the structural formula ##STR1## wherein R is hydrogen, lower alkyl, alkali metal, or a polyhydroxylamine salt, R.sup.1 is hydrogen, lower alkyl, arylalkyl, aryl, cycloalkyl or cycloalkylalkyl, R.sup.2 is hydrogen or lower alkyl, A is --CH.dbd.CH-- or --(CH.sub.2).sub.2, n is 1 to 4, n' is 0, 1 or 2, q is 1 to 10 and m is 0 to 8, and including all stereoisomers thereof.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease, and as such are useful in inhibiting platelet aggregation.

Abstract: 7-Oxabicycloheptane substituted oxa prostaglandin analogs are provided having the structural formula ##STR1## wherein R is OH, ##STR2## (wherein R.sup.3 is lower alkyl, aryl, arylalkyl or lower alkylamino), ##STR3## (wherein R.sup.4 and R.sup.5 are the same or different and can be H, alkyl, aryl or arylalkyl, and R.sup.6 is alkyl or O-alkyl); R.sup.1 is lower alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl; R.sup.2 is hydrogen or lower alkyl; A is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; n is 1 to 4, and m is 1 to 8, and including all stereoisomers thereof.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane substituted oxo prostaglandin analogs are provided having the structural formula ##STR1## wherein R is hydrogen, lower alkyl, alkali metal or trihydroxymethylaminomethane, R.sup.1 is lower alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl, R.sup.2 is hydrogen or lower alkyl, A is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --, n is 1 to 4, and m is 1 to 8, and including all stereoisomers thereof.The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.

Abstract: 7-Oxabicycloheptane substituted prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.